

In the Claims:

This listing of the claims will replace all other prior versions and listing of claims.

1-17. (Canceled)

18. (Previously Presented) A diagnostic process comprising analyzing for the presence of the polypeptide of claim 21 in a sample derived from a host.

19-20. (Canceled).

21. (Previously Presented) An isolated protein comprising an amino acid sequence selected from the group consisting of:

amino acid residues 1 to 337 of SEQ ID NO:2; and

amino acid residues 2 to 337 of SEQ ID NO:2.

22. (Previously Presented) The isolated protein of claim 21 which comprises amino acid sequence (a).

23. (Previously Presented) The isolated protein of claim 21 which comprises amino acid sequence (b).

24. (Previously Presented) The isolated protein of claim 21 wherein the amino acid sequence further comprises a heterologous polypeptide.

25. (Previously Presented) The isolated protein of claim 21 wherein said isolated protein is glycosylated.

26. (Previously Presented) The isolated protein of claim 21 wherein said isolated protein is fused to polyethylene glycol.

27. (Previously Presented) A protein produced by a method comprising:
- (a) expressing the protein of claim 21 by a cell; and
 - (b) recovering the protein.
28. (Previously Presented) A composition comprising the isolated protein of claim 21 and a pharmaceutically acceptable carrier.
29. (Previously Presented) An isolated protein comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 97184;
 - (b) an amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 97184; and
 - (c) an amino acid sequence of the mature polypeptide encoded by the cDNA in ATCC Deposit No. 97184.
30. (Previously Presented) The isolated protein of claim 29 which comprises amino acid sequence (a).
31. (Previously Presented) The isolated protein of claim 29 which comprises amino acid sequence (b).
32. (Previously Presented) The isolated protein of claim 29 which comprises amino acid sequence (c).
33. (Previously Presented) The isolated protein of claim 29 wherein the amino acid sequence further comprises a heterologous polypeptide.
34. (Previously Presented) The isolated protein of claim 29 wherein said isolated protein is glycosylated.

35. (Previously Presented) The isolated protein of claim 29 wherein said isolated protein is fused to polyethylene glycol.
36. (Previously Presented) A protein produced by a method comprising:
- (a) expressing the protein of claim 29 by a cell; and
 - (b) recovering the protein.
37. (Previously Presented) A composition comprising the isolated protein of claim 29 and a pharmaceutically acceptable carrier.
38. (Previously Presented) An isolated protein comprising a first amino acid sequence 90% or more identical to a second amino acid sequence selected from the group consisting of:
- (a) amino acid residues 1 to 337 of SEQ ID NO:2; and
 - (b) amino acid residues 2 to 337 of SEQ ID NO:2.
39. (Previously Presented) The isolated protein of claim 38 wherein the first amino acid sequence is 90% or more identical to the second amino acid sequence (a).
40. (Previously Presented) The isolated protein of claim 38 wherein the first amino acid sequence is 90% or more identical to the second amino acid sequence (b).
41. (Previously Presented) The isolated protein of claim 38 wherein the first amino acid sequence is 95% or more identical to the second amino acid sequence (a).
42. (Previously Presented) The isolated protein of claim 38 wherein the first amino acid sequence is 95% or more identical to the second amino acid sequence (b).
43. (Previously Presented) The isolated protein of claim 38 wherein the amino acid sequence further comprises a heterologous polypeptide.

44. (Previously Presented) The protein of claim 38 wherein said isolated protein is glycosylated.
45. (Previously Presented) The protein of claim 38 wherein said isolated protein is fused to polyethylene glycol.
46. (Previously Presented) A protein produced by a method comprising:
- (a) expressing the protein of claim 38 by a cell; and
 - (b) recovering the protein.
47. (Previously Presented) A composition comprising the isolated protein of claim 38 and a pharmaceutically acceptable carrier.
48. (Previously Presented) An isolated protein comprising a first amino acid sequence 90% or more identical to a second amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 97184;
 - (b) an amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 97184; and
 - (c) an amino acid sequence of the mature polypeptide encoded by the cDNA in ATCC Deposit No. 97184.
49. (Previously Presented) The isolated protein of claim 48 wherein the first amino acid sequence is 90% or more identical to the second amino acid sequence (a).
50. (Previously Presented) The isolated protein of claim 48 wherein the first amino acid sequence is 90% or more identical to the second amino acid sequence (b).
51. (Previously Presented) The isolated protein of claim 48 wherein the first amino acid sequence is 90% or more identical to the second amino acid sequence (c).

52. (Previously Presented) The isolated protein of claim 48 wherein the first amino acid sequence is 95% or more identical to the second amino acid sequence (a).
53. (Previously Presented) The isolated protein of claim 48 wherein the first amino acid sequence is 95% or more identical to the second amino acid sequence (b).
54. (Previously Presented) The isolated protein of claim 48 wherein the first amino acid sequence is 95% or more identical to the second amino acid sequence (c).
55. (Previously Presented) The isolated protein of claim 48 wherein the amino acid sequence further comprises a heterologous polypeptide.
56. (Previously Presented) The isolated protein of claim 48 wherein said isolated protein is glycosylated.
57. (Previously Presented) The isolated protein of claim 48 wherein said isolated protein is fused to polyethylene glycol.
58. (Previously Presented) A protein produced by a method comprising:
 (a) expressing the protein of claim 48 by a cell; and
 (b) recovering the protein.
59. (Previously Presented) A composition comprising the isolated protein of claim 48 and a pharmaceutically acceptable carrier.

60. (Previously Presented) An isolated protein comprising an amino acid sequence selected from the group consisting of:
- (a) amino acid residues 1 to 337 of SEQ ID NO:2, wherein the protein has at least one conservative substitution; and
 - (b) an amino acid sequence comprising a fragment of amino acid residues 1 to 337 of SEQ ID NO:2, wherein the fragment binds an antibody that specifically binds to a polypeptide having the sequence of SEQ ID NO:2.
61. (Previously Presented) The isolated protein of claim 60 which comprises amino acid sequence (a).
62. (Previously Presented) The isolated protein of claim 60 which comprises amino acid sequence (b).
63. (Previously Presented) The isolated protein of claim 60 wherein the amino acid sequence further comprises a heterologous polypeptide.
64. (Previously Presented) The isolated protein of claim 60 wherein said isolated protein is glycosylated.
65. (Previously Presented) The isolated protein of claim 60 wherein said isolated protein is fused to polyethylene glycol.
66. (Previously Presented) A protein produced by a method comprising:
- (a) expressing the protein of claim 60 by a cell; and
 - (b) recovering the protein.
67. (Previously Presented) A composition comprising the isolated protein of claim 60 and a pharmaceutically acceptable carrier.

68. (Previously Presented) An isolated protein comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 97184, wherein the amino acid sequence has at least one conservative substitution; and
 - (b) a fragment of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 97184, wherein the fragment binds an antibody that specifically binds to a polypeptide having the sequence of SEQ ID NO:2.
69. (Previously Presented) The isolated protein of claim 68 which comprises amino acid sequence (a).
70. (Previously Presented) The isolated protein of claim 68 which comprises amino acid sequence (b).
71. (Previously Presented) The isolated protein of claim 68 wherein the amino acid sequence further comprises a heterologous polypeptide.
72. (Previously Presented) The isolated protein of claim 68 wherein said isolated protein is glycosylated.
73. (Previously Presented) The isolated protein of claim 68 wherein said isolated protein is fused to polyethylene glycol.
74. (Previously Presented) A protein produced by a method comprising:
- (a) expressing the protein of claim 68 by a cell; and
 - (b) recovering the protein.
75. (Previously Presented) A composition comprising the isolated protein of claim 68 and a pharmaceutically acceptable carrier.

76. (Previously Presented) An isolated protein comprising at least 30 contiguous amino acid residues of SEQ ID NO:2.
77. (Previously Presented) The isolated protein of claim 76 wherein the isolated protein comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.
78. (Previously Presented) The isolated protein of claim 76 wherein the isolated protein binds an antibody that specifically binds to a polypeptide having the sequence of SEQ ID NO:2.
79. (Previously Presented) The isolated protein of claim 76 wherein the amino acid sequence further comprises a heterologous polypeptide.
80. (Previously Presented) The isolated protein of claim 76 wherein said isolated protein is glycosylated.
81. (Previously Presented) The isolated protein of claim 76 wherein said isolated protein is fused to polyethylene glycol.
82. (Previously Presented) A protein produced by a method comprising:
 (a) expressing the protein of claim 76 by a cell; and
 (b) recovering the protein.
83. (Previously Presented) A composition comprising the isolated protein of claim 76 and a pharmaceutically acceptable carrier.
84. (Previously Presented) An isolated protein comprising at least 30 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 97184.

85. (Previously Presented) The isolated protein of claim 84 wherein the isolated protein comprises at least 50 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 97184.
86. (Previously Presented) The isolated protein of claim 84 wherein the isolated protein binds an antibody that specifically binds to a polypeptide having the sequence of SEQ ID NO:2.
87. (Previously Presented) The isolated protein of claim 84 wherein the amino acid sequence further comprises a heterologous polypeptide.
88. (Previously Presented) The isolated protein of claim 84 wherein said isolated protein is glycosylated.
89. (Previously Presented) The isolated protein of claim 84 wherein said isolated protein is fused to polyethylene glycol.
90. (Previously Presented) A protein produced by a method comprising:
 (a) expressing the protein of claim 84 by a cell; and
 (b) recovering the protein.
91. (Previously Presented) A composition comprising the isolated protein of claim 84 and a pharmaceutically acceptable carrier.